

14 MAY 2026

PACIFIC EDGE OPENS NZ\$6 MILLION RETAIL OFFER

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge Limited (**Pacific Edge** or the **Company**) (NZX/ASX: PEB) today announces the opening of its retail offer to eligible existing shareholders to raise up to NZ\$6 million, with the ability to accept oversubscriptions at Pacific Edge’s discretion (**Retail Offer**).

The Retail Offer is further to the announcement on Wednesday, 13 May 2026 in respect of Pacific Edge’s successful placement (the **Placement**) of NZ\$25.4 million of new ordinary shares to certain investors at a price of NZ\$0.17 per share.

Please refer to the presentation dated Friday, 8 May 2026 and released by NZX and ASX on Monday, 11 May 2026 for further information, and the Retail Offer Document attached to this announcement for the terms and conditions of the Retail Offer.

The Retail Offer is open to “Eligible Shareholders”, who are all persons recorded on Pacific Edge’s share register at 7:00pm NZST on Friday, 8 May 2026 as being a holder of Pacific Edge shares and having an address in New Zealand.

Eligible Shareholders are able to apply for up to a maximum of NZ\$50,000 of new shares per shareholder at NZ\$0.17 per share, the same price per share offered to investors that took part in the Placement. Pacific Edge can elect to accept oversubscriptions at its discretion to ensure that it has sufficient flexibility to cater for demand from its retail shareholder base. The Retail Offer is not underwritten.

The shares issued under the Retail Offer will rank equally with, and be of the same class, as Pacific Edge’s ordinary shares quoted on the NZX Market.

The key dates of the Retail Offer are as follows:

- Record Date: 7:00pm NZST on Friday, 8 May 2026
- Retail Offer Opens and Offer Document released: Thursday, 14 May 2026
- Retail Offer Closing Date: 5:00pm NZST on Thursday, 28 May 2026
- Settlement and Allotment: Thursday, 4 June 2026

The Placement and Retail Offer are aimed at ensuring Pacific Edge has additional resources and capacity to support ongoing operations and growth, support the company to achieve Medicare re-coverage, and continue evidence generation, product development and innovation.

Chairman, Simon Flood said: “We are delighted with the investor support we have received in the Placement and are pleased to offer the same opportunity to all our retail shareholders. The new capital will allow us to consolidate our market position in bladder cancer diagnostics. It will support the Company and its operations to regain Medicare coverage and assist our move towards the broader adoption of our tests with opportunities in the US and in the Asia Pacific Region. We are determined not to lose that momentum.”

NOT FOR DISTRIBUTION OR RELEASE INTO THE UNITED STATES

Eligible Shareholders can apply for shares under the Retail Offer online at www.pacificedge.capitalraise.co.nz or alternatively complete and return a hard copy Application Form (which is available on request from Pacific Edge's Share Registrar, MUFG Pension & Market Services) before 5.00pm NZST on the Closing Date, which is Thursday, 28 May 2026 (unless the Retail Offer is extended). Applications received after the Closing Date may not be accepted.

To request a hard copy Application Form, please contact Pacific Edge's Share Registrar: MUFG Pension & Market Services Level 30, PwC Tower 15 Customs Street West Auckland 1010:

- Telephone +64 9 375 5998
- Email: enquiries.nz@cm.mpms.mufg.com

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW OF PACIFIC EDGE

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.